Aligos Therapeutics logo

Aligos Therapeutics Share Price (NASDAQ: ALGS)

$8.52

0.82

(10.65%)

Live

Last updated on

Check the interactive Aligos Therapeutics Stock chart to analyse performance

Aligos Therapeutics stock performance

as on August 18, 2025 at 11:51 PM IST

  • Today's Low:$8.24
    Today's High:$8.68

    Day's Volatility :5.07%

  • 52 Weeks Low:$3.76
    52 Weeks High:$46.80

    52 Weeks Volatility :91.97%

Aligos Therapeutics Stock Returns

PeriodAligos Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
30.73%
2.3%
0.0%
6 Months
-66.21%
-5.8%
0.0%
1 Year
-45.96%
-10.9%
0.0%
3 Years
-77.68%
2.8%
-11.6%

Aligos Therapeutics Inc Key Stats

Check Aligos Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$7.7
Open
$7.7
Today's High
$8.68
Today's Low
$8.24
Market Capitalization
$53.5M
Today's Volume
$54.6K
52 Week High
$46.8
52 Week Low
$3.76
Revenue TTM
$3.2M
EBITDA
$-77.6M
Earnings Per Share (EPS)
$-13.27
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-87.74%

Stock Returns calculator for Aligos Therapeutics Stock including INR - Dollar returns

The Aligos Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Aligos Therapeutics investment value today

Current value as on today

₹63,863

Returns

₹36,137

(-36.14%)

Returns from Aligos Therapeutics Stock

₹40,211 (-40.21%)

Dollar Returns*

₹4,073 (+4.07%)

Indian investors sentiment towards Aligos Therapeutics Stock

-6%

Period: Jul 18, 2025 to Aug 17, 2025. Change in 30 Days versus previous period

Search interest for Aligos Therapeutics Stock from India on INDmoney has decreased by -6% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Aligos Therapeutics Inc

  • Name

    Holdings %

  • Adage Capital Partners Gp LLC

    6.69%

  • Deep Track Capital, LP

    6.39%

  • Alyeska Investment Group, L.P.

    5.93%

  • Woodline Partners LP

    4.54%

  • Hudson Bay Capital Management LP

    3.47%

  • Heights Capital Management Inc

    3.47%

Analyst Recommendation on Aligos Therapeutics Stock

Rating
Trend

Buy

    75%Buy

    25%Hold

    0%Sell

Based on 8 Wall street analysts offering stock ratings for Aligos Therapeutics(by analysts ranked 0 to 5 stars)

Aligos Therapeutics Share Price Target

What analysts predicted

Upside of 960.25%

Target:

$90.33

Current:

$8.52

Aligos Therapeutics share price target is $90.33, a slight Upside of 960.25% compared to current price of $8.52 as per analysts' prediction.

Aligos Therapeutics Stock Insights

  • Price Movement

    In the last 6 months, ALGS stock has moved down by -66.2%
  • Increasing Revenue

    Revenue is up for the last 2 quarters, 311.0K → 965.0K (in $), with an average increase of 67.8% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 43.08M → -15.86M (in $), with an average decrease of 136.8% per quarter
  • ALGS vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 67.4% return, outperforming this stock by 108.7%
  • ALGS vs ALNY (3 yr)

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 100.9% return, outperforming this stock by 180.1%
  • Price to Sales

    ForALGS every $1 of sales, investors are willing to pay $18.9, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.6 for every $1 of sales.

Aligos Therapeutics Technicals Summary

Sell

Neutral

Buy

Aligos Therapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Aligos Therapeutics Inc Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Aligos Therapeutics Inc logo
-10.88%
-66.21%
-45.96%
-77.68%
-97.93%
Regeneron Pharmaceuticals, Inc. logo
6.39%
-14.65%
-51.51%
-6.14%
-7.82%
Beone Medicines Ltd logo
10.08%
34.96%
66.94%
83.8%
36.85%
Vertex Pharmaceuticals Incorporated logo
-14.33%
-15.0%
-19.52%
31.35%
45.44%
Alnylam Pharmaceuticals, Inc. logo
40.06%
79.56%
63.55%
107.86%
227.15%

About Aligos Therapeutics Inc

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Organization
Aligos Therapeutics
Employees
70
CEO
Dr. Lawrence M. Blatt MBA, Ph.D.
Industry
Health Technology

Key Management of Aligos Therapeutics Inc

NameTitle
Dr. Lawrence M. Blatt MBA, Ph.D.
CEO, President & Chairman of the Board
Ms. Lesley Ann Calhoun CPA
Executive VP, CFO & COO
Ms. Laura Kavanaugh
VP & Head of Legal
Ms. Kristina Engeseth M.B.A.
Senior VP and Head of People & Culture
Dr. Sushmita M. Chanda DABT, Ph.D.
Executive Vice President & Chief Development Officer
Dr. David B. Smith Ph.D.
Executive VP & Head of Chemical Operations
Dr. Tse-I Lin Ph.D.
Senior VP of Early Compound Development & Belgian Site Head
Dr. Hardean E. Achneck M.D.
Executive VP & Chief Medical Officer
Dr. Kieron Wesson Ph.D.
Vice President & Head of Chemistry Manufacturing Controls

Important FAQs about investing in ALGS Stock from India :

What is Aligos Therapeutics share price today?

Aligos Therapeutics share price today is $8.52 as on . Aligos Therapeutics share today touched a day high of $8.68 and a low of $8.24.

What is the 52 week high and 52 week low for Aligos Therapeutics share?

Aligos Therapeutics share touched a 52 week high of $46.80 and a 52 week low of $3.76. Aligos Therapeutics stock price today, is trending at $8.52, lower by 81.79% versus the 52 week high.

How to invest in Aligos Therapeutics Stock (ALGS) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Aligos Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Aligos Therapeutics Shares that will get you 0.1761 shares as per Aligos Therapeutics share price of $8.52 per share as on August 18, 2025 at 11:51 PM IST.

What is the minimum amount required to buy Aligos Therapeutics Stock (ALGS) from India?

Indian investors can start investing in Aligos Therapeutics (ALGS) shares with as little as ₹87.3775 or $1 (as of August 18, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹873.77 in Aligos Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 18, 2025). Based on Aligos Therapeutics share’s latest price of $8.52 as on August 18, 2025 at 11:51 PM IST, you will get 1.1737 shares of Aligos Therapeutics. Learn more about fractional shares .

What are the returns that Aligos Therapeutics has given to Indian investors in the last 5 years?

Aligos Therapeutics stock has given -97.93% share price returns and 16.91% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?